Clinical Trials
As part of the CIRM Alpha Stem Cell Clinics Network, the City of Hope Alpha Stem Cell Clinic is pursuing its goal to accelerate the development and delivery of stem cell therapies to patients through high quality clinical trials.
Ongoing trials include:
Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T-Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinged-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma (COH Protocol #13384)
Status of enrollment: Open to accrual
Disease indication:
-
Malignant glioma
-
Refractory brain neoplasm
-
Recurrent brain neoplasm
-
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With Relapsed or Refractory CD123+ Acute Myeloid Leukemia (COH Protocol #13272)
Status of enrollment: Open to accrual
Disease indication:
-
Relapsed acute myeloid leukemia
-
Refractory acute myeloid leukemia
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) (COH Protocol #15209)
Status of enrollment: Open to accrual
Disease indication:
-
B cell non-Hodgkin lymphoma (NHL)
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas (COH Protocol #14108)
Status of enrollment: Open to accrual
Disease indication:
Status of enrollment: Open to accrual
Disease indication:
-
Adult anaplastic astrocytoma
-
Adult anaplastic oligoastrocytoma
-
Adult anaplastic oligodendroglioma
-
Adult glioblastoma
-
Adult gliosarcoma
-
Recurrent adult brain tumor
-
Glioma
Trial Contact:
Jana Portnow, M.D.
626-218-9200
jportnow@coh.org
Study details at clinicaltrials.gov
An Exploratory Phase 1/2 Trial To Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) (COH Protocol #17198)
Jana Portnow, M.D.
626-218-9200
jportnow@coh.org
Study details at clinicaltrials.gov
An Exploratory Phase 1/2 Trial To Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) (COH Protocol #17198)
Status of enrollment: Open to accrual
Disease indication:
- Non-Hodgkin lymphoma,
- Large B cell diffuse lymphoma
- Follicular lymphoma
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (COH Protocol #17273)
Status of enrollment: Open to accrual
Disease indication:
Status of enrollment: Open to accrual
Disease indication:
- Relapsed or refractory chronic lymphocytic leukemia
- Relapsed or refractory small lymphocytic lymphoma
An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma (COH Protocol #17405)
Status of enrollment: Open to accrual
Disease indication:
Status of enrollment: Open to accrual
Disease indication:
- Relapsed or refractory multiple myeloma
A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: A Non-Myeloablative Conditioning Regimen and CD4+ T Cell-Depleted Haploidentical Hematopoietic Transplant (COH Protocol #16453)
Status of enrollment: Open to accrual
Disease indication:
Status of enrollment: Open to accrual
Disease indication:
- Sickle cell disease
Trial Contact:
Joseph Rosenthal, M.D.
626-256-4673
jrosenthal@coh.org
Study details at clinicaltrials.gov
Joseph Rosenthal, M.D.
626-256-4673
jrosenthal@coh.org
Study details at clinicaltrials.gov
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) (COH Protocol #15209)
Status of enrollment: Open to accrual
An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) (COH Protocol #17198)
Status of enrollment: Open to accrual
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma (COH Protocol # 16064)
Status of enrollment: Open to accrual
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma (COH Protocol # 18101)
Status of enrollment: Open to accrual
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies (COH Protocol #17166)
Status of enrollment: Open to accrual
A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients with Brain and/or Leptomeningeal Metastases from HER2 Positive Cancers (COH Protocol #17237).
Status of enrollment: Open to accrual
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
(COH Protocol #18388)
(COH Protocol #18388)
Status of enrollment: Open to accrual
Trial contact:
Anthony Stein
Anthony Stein
626-218-2405
astein@coh.org
astein@coh.org
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients with CS1+Multiple Myeloma (COH Protocol #17403)
Status of enrollment: Open to accrual
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High- Risk Large B-Cell Lymphoma (ZUMA-12) (COH Protocol #18344)
Status of enrollment: Open to accrual
An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination with Pembrolizumab in Subjects with Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma (COH Protocol #18477)
Status of enrollment: Open to accrual
A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer (COH Protocol #18389)
Status of enrollment: Open to accrual
A Phase I Study to Evaluate PSCA-targeting Chimeric Antigen Receptor (CAR)-T cells for Patients with Metastatic Castration Resistant Prostate Cancer (COH Protocol #17483)
Status of enrollment: Open to accrual
Trial contact:
Tanya Dorff, M.D.
Tanya Dorff, M.D.
626-218-9200
tdorff@coh.org
tdorff@coh.org
A Phase 1, Open Label, Non-Randomized, Multi-Center Trial of AB-205 in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation (COH Protocol #18506)
Status of enrollment: Open to accrual
A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy with CSL200 (Autologous Enriched CD34+ Cell Fraction that Contains CD34+ Cells Transduced with Lentiviral Vector Encoding Human Gamma-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects with Severe Sickle Cell Disease (COH Protocol #19183)
Status of enrollment: Open to accrual